Production (Stage)
ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 351.00K | 332.30K | 315.90K | 287.00K | 260.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 351.00K | 332.30K | 315.90K | 287.00K | 260.10K |
| Cost of Revenue | 1.03M | 1.75M | 1.77M | 1.76M | 1.74M |
| Gross Profit | -681.10K | -1.42M | -1.46M | -1.47M | -1.48M |
| SG&A Expenses | 6.82M | 8.43M | 9.02M | 9.64M | 9.45M |
| Depreciation & Amortization | 2.16M | 2.19M | 2.23M | 2.15M | 2.30M |
| Other Operating Expenses | 356.00K | 279.80K | 285.50K | 291.60K | 261.10K |
| Total Operating Expenses | 11.86M | 14.22M | 14.46M | 14.78M | 14.72M |
| Operating Income | -11.51M | -13.89M | -14.14M | -14.49M | -14.46M |
| Income Before Tax | -25.89M | -31.16M | -31.41M | -34.77M | -35.87M |
| Income Tax Expenses | -1.49M | -4.29M | -4.30M | -4.30M | -4.30M |
| Earnings from Continuing Operations | -24.39 | -26.86 | -27.12 | -30.47 | -31.57 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -24.39M | -26.86M | -27.12M | -30.47M | -31.57M |
| EBIT | -11.51M | -13.89M | -14.14M | -14.49M | -14.46M |
| EBITDA | -9.68M | -12.00M | -12.21M | -12.64M | -12.45M |
| EPS Basic | -0.33 | -0.38 | -0.39 | -0.49 | -0.54 |
| Normalized Basic EPS | -0.11 | -0.14 | -0.14 | -0.19 | -0.22 |
| EPS Diluted | -0.34 | -0.39 | -0.39 | -0.49 | -0.55 |
| Normalized Diluted EPS | -0.11 | -0.14 | -0.14 | -0.19 | -0.22 |
| Average Basic Shares Outstanding | 288.25M | 283.92M | 281.56M | 256.46M | 224.14M |
| Average Diluted Shares Outstanding | 288.25M | 283.92M | 281.56M | 256.46M | 224.14M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |